Coriell Institute for Medical Research

Name

Coriell Institute for Medical Research

Legal name

Coriell Institute for Medical Research

Website

https://coriell.org

Company type

Private

Founded year

1953

Operating status

Operating

Headcount range

251–500 employees

Ownership category

akta.pro rank

Product category

Biomedical Research and Biobanking Services

NAICS

Medical and Diagnostic Laboratories (6215), Scientific Research and Development Services (5417)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

akta.pro secondary industries

Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Clinical Research & Trial Central Laboratories (HLAFAMAL)

Keywords

• Biomedical biobanking services
• Biological sample repository
• Induced pluripotent stem cells
• Genomics and epigenomics research
• Clinical trial sample management

Headquarters

HQ city

Camden

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Revenue model

1. Sample Distribution and Sales: Sale and distribution of biological samples including cell lines, stem cells, DNA, and RNA to researchers worldwide. Samples are priced by customer type (NEI-grantee, academic/non-profit, commercial) with standard shipping and handling fees.
2. NIH Contracts and Grants: Research awards and contracts from National Institutes of Health, including scientific management of NIMH Repository and hosting biobanks for NIGMS, NINDS, NHGRI, NEI, and NIA. One of the top recipients of NIH research awards in New Jersey.
3. Foundation and Charitable Funding: Grant funding from foundations such as the William G. Rohrer Charitable Foundation ($500,000 for Cancer Biobank) and investment from NJEDA ($41 million for Innovation Center).
4. Custom Research and Laboratory Services: Bespoke biobanking, bioinformatics, cell culture, and assay development services for pharmaceutical companies and research organizations requiring specialized laboratory expertise.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Coriell Institute for Medical Research operates one of the world's most important biobanks, housing nearly 3 million vials of cell cultures and millions of DNA samples, distributing biological specimens (cell lines, stem cells, DNA, RNA) to researchers in 80+ countries. It provides NIH-supported repository services for NIGMS, NINDS, NHGRI, NEI, and NIA, alongside custom biobanking, iPSC, cellular/molecular, bioinformatics, genomics/epigenomics, and clinical trial support services for academic, pharmaceutical, and government researchers.

Product overview

Coriell Institute for Medical Research operates as a globally-recognized biobank and biomedical research organization with a unified platform combining biological sample distribution and research services. The core offering centers on the NIGMS Human Genetic Cell Repository—one of the world's most important biobanks established in 1972—alongside NIH-funded repositories for NINDS, NHGRI, NEI, and NIA. Supporting services include Stem Cells and iPSC Services (reprogramming, characterization, expansion, gene editing), Cellular and Molecular Services (biomarkers, cell culture, nucleic acid isolation), Bioinformatics Services (gene expression search, SNP search, star allele search tools), and Core Facilities (animal studies, cell imaging, flow cytometry, genomics). Research initiatives include the Camden Cancer Research Center (three-way partnership with Cooper), the Camden Opioid Research Initiative, and the NCI-funded Epigenetic Therapies SPORE. The company also offers clinical trial support and maintains web-based search tools (SNP Search, Star Allele Search) for querying genomic data.

Differentiator

Problem solved

Functional benefit

Brands

• Camden Cancer Research Center (CCRC): A three-way partnership between Coriell, Cooper University Health Care, and Cooper Medical School of Rowan University to study cancer biology and develop new therapies. Established in 2023 with an initial investment of $30 million over 10 years.
• NJ Coriell Labs Innovation Center
• NEI Genetic Repositories

Quantifiable outcome

• Enabled discovery of ATM gene (causes ataxia telangiectasia and breast cancer) in 1995 using samples from NIGMS repository
• +2 more outcomes

Named customers10 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

Partnerships

Seven partnerships are on record, tiered core, major and notable.

• Cooper University Health CarecoreStrategic or Co-development Partner · 1 July 2023Three-way partnership between Coriell, Cooper University Health Care, and Cooper Medical School of Rowan University to establish the Camden Cancer Research Center (CCRC). The CCRC is the first basic cancer research center in southern New Jersey, with an initial investment of $30 million over 10 years. Coriell provides research expertise and biobanking capabilities; Cooper provides clinical expertise and patient access.
• Cooper Medical School of Rowan UniversitycoreStrategic or Co-development Partner · 1 July 2023Three-way partnership forming the Camden Cancer Research Center. The medical school provides academic research capabilities and medical education expertise, complementing Coriell's biobanking and Cooper's clinical care.
• Allen Institute for Cell SciencemajorStrategic or Co-development Partner · 1 January 2016Partnership to house and distribute the Allen Cell Collection, providing scientists with state-of-the-art stem cell lines for observing cell function with unprecedented clarity. New disease-specific iPSCs added in 2024 for hypertrophic cardiomyopathy, skeletal myopathy, and laminopathy.
• National Institutes of Health (Multiple Institutes)coreStrategic or Co-development Partner · 1 January 1960Coriell has served as an NIH-supported cell repository for over 50 years, currently hosting biobanks for NIGMS, NINDS, NHGRI, NEI, and NIA. Also awarded contract for scientific management of NIMH Repository and Genomics Resource. One of the top recipients of NIH awards in New Jersey.
• Van Andel Research InstitutecoreStrategic or Co-development PartnerJoint leadership of the Epigenetics Specialized Program of Research Excellence (SPORE), a National Cancer Institute-funded research grant. The program encompasses three major research projects focused on developing epigenetic therapies for cancer treatment, including CDK9 inhibition, DNMT and EZH1/2 inhibitors, and PARP inhibitor strategies.
• National Eye Institute (NEI)coreStrategic or Co-development PartnerCoriell hosts NEI Genetic Repositories including the AREDS and AREDS2 collections with nearly 5,000 DNA samples available for distribution. These samples support genetics research into causes of eye disease, particularly age-related macular degeneration and cataracts.
• University of PennsylvanianotableStrategic or Co-development PartnerCollaboration with UPenn researchers on bioinformatics and cancer research projects. Part of broader network of research partnerships including Hackensack Meridian Health and Van Andel Research Institute.

Scale indicators10 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Discovery Life Sciences: Discovery Life Sciences provides biospecimen procurement, processing, and biobanking services to pharma and academic researchers. It is comparable to Coriell in offering characterized biological samples and biobanking services, but with a stronger commercial orientation and broader disease-state coverage.
• BioIVT: BioIVT is a leading commercial provider of human biospecimens, including disease-state and normal tissue, blood products, and primary cells. It directly competes with Coriell's sample distribution business, particularly for pharma and biotech customers seeking characterized patient-derived samples with modern procurement workflows.
• Azenta Life Sciences (formerly Brooks Life Sciences): Azenta provides sample management, biobanking, and genomic services to pharmaceutical and academic customers globally. Its automated sample storage and cold-chain logistics capabilities directly compete with Coriell's biobanking infrastructure offerings.
• ATCC (American Type Culture Collection): ATCC is the most direct peer to Coriell, operating a global biological resource center distributing cell lines, microbial strains, and biomaterials to researchers worldwide. Both are nonprofit repositories with NIH-supported mandates and compete for cell line distribution customers in the academic and pharmaceutical research market.
• iSpecimen: iSpecimen operates a digital marketplace for human biospecimens connecting researchers with healthcare providers. It competes with Coriell's sample distribution model by offering a tech-enabled, on-demand procurement experience for researchers needing specific disease-state samples.

Regional players

• Genomics England: Genomics England operates a national genomics repository and biobanking platform serving UK researchers with linked clinical and genomic data. While primarily serving the UK market, it is comparable to Coriell in operating a large-scale government-supported genetic repository for biomedical research.

Emerging players

• Stemcell Technologies: Stemcell Technologies specializes in stem cell research tools, iPSC culture media, and cell isolation products. While more focused on reagents than biobanking, it competes in the iPSC research tools market where Coriell's Allen Cell Collection and Stem Cells services operate.

Broad incumbents

• Charles River Laboratories: Charles River Laboratories provides biological products, cell-based assays, and research services to pharma and biotech clients. While primarily a CRO, its biological products and cell biology services overlap with Coriell's offerings in supporting drug discovery and preclinical research.
• Lonza Bioscience Solutions: Lonza is a global incumbent offering cell biology products, primary cells, and stem cell services across pharmaceutical, biotech, and academic markets. While broader in scope than Coriell, Lonza competes directly in cell culture products, iPSC services, and biobanking solutions for the same research customers.
• Thermo Fisher Scientific (Cell Culture): Thermo Fisher Scientific offers comprehensive cell culture media, reagents, and biological sample services through its Life Sciences Solutions division. As a broad incumbent, it competes with Coriell across multiple touchpoints including cell line authentication, biological samples, and genomic services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/coriell_science
• YouTubeyoutube.com/CoriellInstitute
• Facebookfacebook.com/app_116943498446376
• LinkedInlinkedin.com/company/coriell-institute-for-medical-research

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Coriell Institute for Medical Research